Therapeutic management of patent ductus arteriosus

Arpitha Chiruvolu, Mambarath A. Jaleel

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Management of patent ductus arteriosus (PDA) in premature neonates has always been a challenge to the neonatologist and continues to be a controversial topic. Indications for treatment are not clear. Approximately 40% of ductus arteriosus close spontaneously even in extremely-low-birth-weight neonates. Prophylactic or early pre-symptomatic treatment may unnecessarily expose these babies, in whom the ductus might close spontaneously, to pharmacologic agents and their adverse effects. On the other hand, with advancing postnatal age, delaying treatment could potentially decrease successful medical closure thereby increasing the rate of surgical ligation and the complications associated with surgery. We tried to develop some clinical guidelines for management of PDA in premature neonates based on evidence, or lack thereof, and experience.

Original languageEnglish (US)
Pages (from-to)151-155
Number of pages5
JournalEarly Human Development
Issue number3
StatePublished - Mar 2009


  • Chronic lung disease
  • Ibuprofen lysine
  • Indomethacin
  • Intraventricular hemorrhage
  • Neurodevelopmental impairment
  • Patent ductus arteriosus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology


Dive into the research topics of 'Therapeutic management of patent ductus arteriosus'. Together they form a unique fingerprint.

Cite this